Results 31 to 40 of about 9,558 (217)

Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up. [PDF]

PLoS ONE, 2015
To assess, in a clinical cohort, the efficacy of switching treatment in virologically-suppressed patients to tenofovir/emtricitabine/rilpivirine as a single-tablet regimen (STR) using the PCR signal of the viral load (VL) assay and plasma drug ...
Charlotte Charpentier, Minh Patrick Lê, Véronique Joly, Benoit Visseaux, Sylvie Lariven, Bao Phung, Patrick Yéni, Yazdan Yazdanpanah, Diane Descamps, Gilles Peytavin, Roland Landman   +10 more
doaj   +1 more source

Extension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubility [PDF]

, 2013
Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that feature extension into the entrance channel near Glu138. Complexes of the parent anilinylpyrimidine 1 and the morpholinoethoxy analog 2j with HIV-RT have received ...
Anderson, Karen S., Arnold, Eddy, Bauman, Joseph D., Bollini, Mariela, Cisneros, José A., Das, Kalyan, Frey, Kathleen M., Jorgensen, William L., Spasov, Krasimir A.   +8 more
core   +1 more source

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

Viruses, 2023
Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and ...
Paolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Chiara Molteni, Addolorata Masiello, Giancarlo Orofino, Barbara Menzaghi, Rita Bellagamba, Francesca Vichi, Benedetto Maurizio Celesia, Giordano Madeddu, Giovanni Francesco Pellicanò, Maria Aurora Carleo, Antonio Cascio, Andrea Parisini, Lucia Taramasso, Laura Valsecchi, Leonardo Calza, Stefano Rusconi, Eleonora Sarchi, Salvatore Martini, Olivia Bargiacchi, Katia Falasca, Giovanni Cenderello, Sergio Ferrara, Antonio Di Biagio, Paolo Bonfanti   +28 more
doaj   +1 more source

Dosing antiretroviral medication when crossing time zones: a review [PDF]

, 2016
International tourism continues to increase worldwide, and people living with HIV and their clinicians are increasingly confronted with the problem of how to dose antiretroviral therapy during transmeridian air travel across time zones.
Boffito, Marta, Khoo, Saye, Lewis, Joseph M, Volny-Anne, Alain, Waitt, Catriona   +4 more
core   +1 more source

Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV

International Journal of Infectious Diseases
Objectives: Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for preventing mother-to-child HIV transmission, may have reduced plasma exposure in the second and third trimesters due to increased metabolism/elimination in pregnant women ...
Benjamin Kably, Roland Tubiana, Jade Ghosn, Quentin Le Hingrat, Marc Wirden, Zelie Julia, Naima Hamani, Laurent Mandelbrot, Gilles Peytavin, Minh P Lê   +9 more
doaj   +1 more source

Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells

Pharmaceuticals, 2022
The global burden of cancer necessitates rapid and ongoing development of effective cancer therapies. One promising approach in this context is the repurposing of existing non-cancer drugs for cancer indications.
Saiful Islam, Theodosia Teo, Malika Kumarasiri, Martin Slater, Jennifer H. Martin, Shudong Wang, Richard Head   +6 more
doaj   +1 more source

Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR

Future Journal of Pharmaceutical Sciences, 2021
Background Using a Symmetry C18 (4.6 × 150 mm, 3.5) column, a high-performance liquid chromatographic method for quantification of Rilpivirine and Cabotegravir in active pharmaceutical ingredients was developed and validated.
Anuradha Vejendla, Subrahmanyam Talari, Raju Moturu, S. N. Murthy Boddapati, A. Emmanuel Kola   +4 more
doaj   +1 more source

Towards a Patent Pool for HIV Medicines: The Background [PDF]

, 2010
Recent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time,
Childs, Michelle
core   +2 more sources

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment. [PDF]

, 2016
The goal of this research was to establish a new and innovative framework for cost-effectiveness modeling of HIV-1 treatment, simultaneously considering both clinical and epidemiological outcomes.
Camacho, Ricardo, Ferreira, Diana, Félix, Jorge, Llibre, Josep M, Miners, Alec, Parienti, Jean-Jacques, Smith, Colette, Ustianowski, Andrew, Vandewalle, Björn   +8 more
core   +2 more sources

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source